Nanobiotechnology in Diagnosis, Drug Delivery and Treatment. (Record no. 22367)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11247nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6396363 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114648.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119671794 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781119671770 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6396363 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6396363 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1225551249 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS420 .N366 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610.28 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Rai, Mahendra. |
| 245 10 - TITLE STATEMENT | |
| Title | Nanobiotechnology in Diagnosis, Drug Delivery and Treatment. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (419 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Chapter 1 Nanotechnology: A New Era in the Revolution of Drug Delivery, Diagnosis, and Treatment of Diseases -- 1.1 Introduction -- 1.2 Nanomaterials Used in Diagnosis, Drug Delivery, and Treatment of Diseases -- 1.2.1 Inorganic Nanomaterials -- 1.2.2 Organic Nanomaterials -- 1.3 Role of Nanomaterials in Diagnosis, Drug Delivery, and Treatment -- 1.3.1 In Diagnosis -- 1.3.2 In Drug Delivery and Treatment -- 1.4 Advantages and Challenges Associated with Nanomaterials Used in Drug Delivery, Diagnosis, and Treatment of Diseases -- 1.4.1 Advantages of Nanomaterials -- 1.4.2 Challenges Associated with the Use of Nanomaterials -- 1.5 Conclusion -- References -- Chapter 2 Selenium Nanocomposites in Diagnosis, Drug Delivery, and Treatment -- Nomenclature -- 2.1 Introduction -- 2.2 Nanoselenium: Application in Diagnosis -- 2.3 Nanoselenium and Antitumor Activity -- 2.4 Nanoselenium As a Part of Drug Delivery System -- 2.5 Nanoselenium for Alzheimer's Disease -- 2.6 Antibacterial Activity of Nanoselenium -- 2.7 Nanoselenium in Diabetes Treatment -- 2.8 Other Applications of Nanoselenium -- 2.9 Conclusion -- References -- Chapter 3 Emerging Applications of Nanomaterials in the Diagnosis and Treatment of Gastrointestinal Disorders -- 3.1 Introduction -- 3.2 Properties of Nanomaterials Affecting Their Potential Use in Medicine -- 3.3 Nanomaterials Used in Diagnosis and Treatment of Gastrointestinal Disorders -- 3.3.1 Liposomes -- 3.3.2 Polymers -- 3.3.3 Core-Shell Nanoparticles -- 3.3.4 Quantum Dots (QDs) -- 3.4 Nanoparticle Uptake in the Gastrointestinal Tract -- 3.5 Gastrointestinal Disorders and Their Treatment with Nanomaterials -- 3.6 Nanomaterials: Potential Treatment for Gastric Bacterial Infections -- 3.7 Nanostructures for Colon Cancer Diagnostics and Therapeutics. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.8 Conclusion and Future Perspectives -- References -- Chapter 4 Nanotheranostics: Novel Materials for Targeted Therapy and Diagnosis -- 4.1 Introduction -- 4.2 Magnetic Nanostructures -- 4.3 Gold/Silver-Based Nanomaterials -- 4.4 Quantum Dot-Based -- 4.5 Polymer-Based Nanomaterials -- 4.6 Silica-Based Nanomaterials -- 4.7 Carbon-Based Nanomaterials -- 4.7.1 Fullerene -- 4.7.2 Carbon Quantum Dots -- 4.7.3 Carbon Nanotubes -- 4.7.4 Graphene -- 4.8 Conclusion and Future Perspectives -- References -- Chapter 5 Aptamer-Incorporated Nanoparticle Systems for Drug Delivery -- 5.1 Introduction -- 5.2 Different Types of Aptamers for Drug Delivery -- 5.2.1 Aptamers for Targeting -- 5.2.2 Therapeutic Aptamers -- 5.2.3 Gating/Sensing Aptamers -- 5.3 Aptamer-Conjugated Nanosystems for Targeted Delivery Platforms -- 5.3.1 Aptamer-Based Polymeric Nanoparticles -- 5.3.2 Aptamer-Based Lipid Nanoparticles -- 5.3.3 Aptamer-Based DNA Nanostructures -- 5.3.4 Aptamer-Based Peptide Nanoparticles -- 5.3.5 Aptamer-Based Inorganic Nanoparticles -- 5.4 Aptamer-Conjugated Nanosystems for Smart Delivery Platforms -- 5.4.1 Endogenous Stimuli-Responsive Aptamer-Conjugated Nanosystems -- 5.4.2 Physical Exogenous Stimuli-Responsive Aptamer-Conjugated Nanosystems -- 5.5 Clinical Applications of Aptamers -- 5.6 Conclusion -- References -- Chapter 6 Application of Nanotechnology in Transdermal Drug Delivery -- 6.1 Introduction -- 6.2 What Is the Stratum Corneum (SC)? -- 6.2.1 SC as a Barrier -- 6.3 Nanocarriers -- 6.3.1 Human Skin -- 6.3.2 Interaction Between Nanocarriers and Skin -- 6.4 Properties of Nanocarriers -- 6.4.1 Physicochemical Properties of Nanocarriers for TDD -- 6.4.2 Targeting of Nanocarriers -- 6.5 Drug Delivery Systems -- 6.5.1 TDD -- 6.6 Potentials of Nanotechnology -- 6.7 Enhancement of TDD -- 6.7.1 Physical Approach -- 6.7.2 Chemical Approach. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.8 Contribution of Nanotechnology in TDD in the Future -- 6.9 Conclusion -- References -- Chapter 7 Superparamagnetic Iron Oxide Nanoparticle-Based Drug Delivery in Cancer Therapeutics -- 7.1 Introduction -- 7.2 Magnetic Drug Delivery Systems -- 7.2.1 Surface-Modified SPIONs -- 7.2.2 SPIONs-Encapsulated Polymeric Nanoparticles/Micelles -- 7.2.3 Magnetic Liposomes -- 7.2.4 Magneto-Niosomes -- 7.2.5 Other Magnetic Nanostructures -- 7.3 Magnetic Delivery of Anticancer Drugs -- 7.3.1 Magnetic Delivery of Single Drugs -- 7.3.2 Magnetic Delivery of Dual Drugs -- 7.4 Conclusion -- References -- Chapter 8 Virus-Like Nanoparticle-Mediated Delivery of Cancer Therapeutics -- 8.1 Introduction -- 8.2 Viruses as Bioinspired Delivery Vehicles -- 8.2.1 Plant-Based Virus-Like Nanoparticles -- 8.2.2 Animal-Based Virus-Like Nanoparticles -- 8.2.3 Phage Virus-Like Nanoparticles -- 8.3 Virus-Like Nanoparticle (VLNP) Production -- 8.4 VLNP-Mediated Cancer Drug Delivery -- 8.4.1 Plant Virus-Derived VLNP-Mediated Delivery of Cancer Therapeutics -- 8.4.2 Phage Virus-Derived VLNP-Mediated Delivery of the Cancer Therapeutics -- 8.4.3 Animal Virus-Derived VLNP-Mediated Delivery of Cancer Therapeutics -- 8.5 Conclusions -- References -- Chapter 9 Magnetic Nanoparticles: An Emergent Platform for Future Cancer Theranostics -- 9.1 Introduction -- 9.2 Magnetic Properties of MNPs -- 9.3 Advantages of MNPs in Biomedicine -- 9.4 Preparation of MNPs -- 9.4.1 Physical Methods -- 9.4.2 Chemical Methods -- 9.5 Coating of Magnetic Nanoparticles -- 9.6 Biomedical Applications of MNPs -- 9.6.1 Targeted Drug Delivery -- 9.6.2 Passive Targeting -- 9.6.3 Active Targeting -- 9.6.4 Cancer Diagnostics -- 9.6.5 Magnetic Resonance Imaging (MRI) -- 9.6.6 Magnetic Hyperthermia Therapy -- 9.7 Conclusions -- References -- Chapter 10 Chitosan Nanoparticles: A Novel Antimicrobial Agent. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 10.1 Introduction -- 10.2 Bioactivities of ChNPs -- 10.2.1 Antimicrobial Activity of ChNPs -- 10.2.2 Anticancer Activity of ChNPs -- 10.2.3 Other Biomedical Applications -- 10.3 Factors Affecting the Antimicrobial Activity of ChNPs -- 10.3.1 Intrinsic Factors -- 10.3.2 Extrinsic Factors -- 10.3.3 Microbial Factors -- 10.4 Mode of Action of ChNPs -- 10.4.1 Part of Active Component: Chitosan -- 10.4.2 Part of Microorganisms -- 10.5 Conclusion -- References -- Chapter 11 Sulfur Nanoparticles: Biosynthesis, Antibacterial Applications, and Their Mechanism of Action -- 11.1 Introduction -- 11.2 Mechanisms of Antibiotic Resistance and Combination Therapy -- 11.3 Biosynthesis of Sulfur Nanoparticles (SNPs) -- 11.4 Antibacterial Application of SNPs -- 11.5 Possible Mechanisms for Antibacterial Action -- 11.6 Conclusion -- References -- Chapter 12 Role of Nanotechnology in the Management of Indoor Fungi -- 12.1 Introduction -- 12.2 Indoor Fungal Deterioration -- 12.2.1 Indoor Mycobiota -- 12.2.2 Factors Influencing Indoor Fungal Growth -- 12.3 Conventional Approach Used for the Control of Indoor Fungi -- 12.4 Nanotechnology for the Control of Fungal Growth -- 12.4.1 Metal Nanoparticles -- 12.4.2 Non-metal and Hybrid (Metal/Non-metal) Nanoparticles -- 12.4.3 Nanotechnological Management of Indoor Fungi -- 12.5 Hygienic Coatings and Nanotechnology -- 12.6 Conclusion -- References -- Chapter 13 Nanotechnology for Antifungal Therapy -- 13.1 Introduction -- 13.2 Basic Aspects of Nanotechnology in Medicine -- 13.3 Nanoparticulate Drug Delivery Systems for Refined Antifungal Therapy -- 13.3.1 Metallic Nanoparticles -- 13.3.2 Liposomes -- 13.3.3 Polymeric Nanoparticles -- 13.4 Conclusions and Final Remarks -- References -- Chapter 14 Chitosan Conjugate of Biogenic Silver Nanoparticles: A Promising Drug Formulation with Antimicrobial and Anticancer Activities. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 14.1 Introduction -- 14.2 Conjugation of AgNPs with Natural Polymers -- 14.3 Conjugation of Bio-AgNPs with Chitosan -- 14.4 Methods for Conjugation -- 14.5 Techniques Used for the Characterization of ChBio-AgNPs -- 14.5.1 UV-Visible Spectroscopy -- 14.5.2 X-Ray Diffraction (XRD) Analysis -- 14.5.3 Transmission Electron Microscopy (TEM) -- 14.5.4 Scanning Electron Microscopy (SEM) -- 14.5.5 Dynamic Light Scattering (DLS) and Zeta Potential -- 14.5.6 Atomic Force Microscopy (AFM) -- 14.5.7 Fourier Transform Infrared (FTIR) Spectroscopy -- 14.6 Bioactivities of ChBio-AgNP Conjugate -- 14.6.1 Antibacterial Activity of ChBio-AgNPs -- 14.6.2 Antifungal Activity of ChBio-AgNPs -- 14.6.3 Antioxidant Activity of ChBio-AgNPs -- 14.6.4 Anticancer Efficacy of ChBio-AgNPs -- 14.7 Cytotoxicity Analysis -- 14.7.1 RBC Lysis Assay -- 14.7.2 MTT Assay -- 14.8 Conclusion -- Acknowledgment -- References -- Chapter 15 Leishmaniasis: Where Infection and Nanoparticles Meet -- 15.1 Introduction -- 15.2 Clinical Forms -- 15.3 Epidemiology -- 15.4 Life Cycle and Transmission -- 15.5 Diagnosis, Detection, and Surveillance -- 15.6 Treatment Strategies for Leishmaniasis -- 15.7 Nanotechnological Approach to Leishmaniasis Treatment -- 15.7.1 Polymeric Nanoparticles -- 15.7.2 Inclusion Compounds -- 15.7.3 Dendrimers -- 15.7.4 Liposomes -- 15.7.5 Other Vesicular Nanoparticles -- 15.7.6 Solid Lipid Nanoparticles (SLNs) -- 15.7.7 Micro- and Nanoemulsions -- 15.7.8 Nanodrugs and Nanosuspensions -- 15.7.9 Inorganic Nanoparticles -- 15.8 Conclusion -- References -- Chapter 16 Theranostics and Vaccines: Current Status and Future Expectations -- 16.1 Introduction -- 16.2 The Role of Theranostics and Vaccines in Early Diagnosis and Therapeutic Strategies in Different Diseases -- 16.2.1 Cancer -- 16.2.2 Cardiovascular Disease -- 16.2.3 Neurodegenerative Diseases -- 16.3 Vaccine. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 16.4 Conclusions. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nanoparticles-Therapeutic use. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Razzaghi-Abyaneh, Mehdi. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ingle, Avinash P. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Rai, Mahendra |
| Title | Nanobiotechnology in Diagnosis, Drug Delivery and Treatment |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2020 |
| International Standard Book Number | 9781119671770 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6396363">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6396363</a> |
| Public note | Click to View |
No items available.